3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasm Metastasis
10
Carcinoma, Medullary
10
Thyroid Neoplasms
5
Lung Neoplasms
5
Prostatic Neoplasms
3
Neoplasms
3
Adenocarcinoma
3
Familial medullary thyroid carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Biliary Tract Neoplasms
1
Aggression
1
Advanced Breast Cancer
1
Interventions
Gemcitabine
28
pembrolizumab
24
Cisplatin
24
Fluorouracil
11
Leucovorin
10
Oxaliplatin
8
Nivolumab
7
Capecitabine
6
Irinotecan
5
Drug Therapy
5
pemigatinib
4
futibatinib
4
Paclitaxel
4
Carboplatin
4
ivosidenib
3
durvalumab
3
derazantinib
3
Folfox protocol
3
Bevacizumab
3
zanidatamab
2
spartalizumab
2
olutasidenib
2
lenvatinib
2
infigratinib
2
fludarabine
2
budigalimab
2
Trastuzumab
2
Ipilimumab
2
Injections
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Cholangiocarcinoma
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts